Fig. 7: Repression of CDK7 inhibits CCA cells and sensitizes CCA cells to ABT-263.

a HuCCT1 and HuH28 cells were transfected with indicated siRNA for 48 h. CDK7 and MCL1 protein expression was analyzed by western blotting. b HuCCT1 and HuH28 cells were exposed to ABT-263 at indicated concentration for 48 h after being transfected with indicated siRNA for 24 h. Cell viability was measured by CCK-8 assay and cell proliferation was detected using the BrdU proliferation ELISA kit. Data represent mean ± SEM of three independent replicates (*P < 0.05; **P < 0.01; ***P < 0.001). c HuCCT1 and HuH28 cells were treated with a novel CDK7 inhibitor ICEC0942 at different concentrations for 72 h. Cell viability was measured by CCK-8 assay. d HuCCT1 and HuH28 cells were exposed to ICEC0942 at indicated concentrations for 24 h. RNP2, RNP2 phosphorylation and MCL1 expression were analyzed by western blotting. e HuCCT1 and HuH28 cells were treated with ICEC0942 and ABT-263 at indicated concentrations for 48 h. Cell viability was measured by CCK-8 assay. Data represent mean ± SEM of three independent replicates. (*P < 0.05; **P < 0.01; ***P < 0.001). f HuCCT1 and HuH28 cells were treated with ICEC0942 and ABT-263 at above mentioned concentrations for 48 h. Cleaved PARP protein expression was analyzed by western blotting